Download PDF
Semin intervent Radiol 2014; 31(02): 187-192
DOI: 10.1055/s-0034-1373793
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

The Role of PET Imaging Before, During, and After Percutaneous Hepatic and Pulmonary Tumor Ablation

Eric D. McLoney
1   Department of Radiology, University of North Carolina, Chapel Hill, North Carolina
,
Ari J. Isaacson
1   Department of Radiology, University of North Carolina, Chapel Hill, North Carolina
,
Patrick Keating
1   Department of Radiology, University of North Carolina, Chapel Hill, North Carolina
› Author Affiliations
Further Information

Publication History

Publication Date:
21 May 2014 (online)

Also available at
    Permissions and Reprints

Abstract

The combination of anatomic and metabolic information provided by positron emission tomography (PET)/computed tomography makes it an important imaging modality to be obtained in conjunction with percutaneous ablation of primary and secondary malignancies of the lungs and liver. Advantages include more accurate preprocedural staging to determine appropriate treatment options, intraprocedural guidance to target difficult-to-see lesions, and postprocedural detection of residual or recurrent disease. Future applications of PET include strategies for intraprocedural guidance with real-time determination of incompletely ablated tumor, and combined PET/magnetic resonance imaging before, during, and after ablation for greater sensitivity to detect disease.

Keywords

PET/CT - percutaneous ablation - hepatic tumors - pulmonary tumors - interventional radiology
 

  • References

  • 1 Crocetti L, de Baere T, Lencioni R. Quality improvement guidelines for radiofrequency ablation of liver tumours. Cardiovasc Intervent Radiol 2010; 33 (1) 11-17
    CrossrefPubMedGoogle Scholar
  • 2 Kuehl H, Rosenbaum-Krumme S, Veit-Haibach P , et al. Impact of whole-body imaging on treatment decision to radio-frequency ablation in patients with malignant liver tumors: comparison of [18F]fluorodeoxyglucose-PET/computed tomography, PET and computed tomography. Nucl Med Commun 2008; 29 (7) 599-606
    CrossrefPubMedGoogle Scholar
  • 3 Georgakopoulos A, Pianou N, Kelekis N, Chatziioannou S. Impact of 18F-FDG PET/CT on therapeutic decisions in patients with colorectal cancer and liver metastases. Clin Imaging 2013; 37 (3) 536-541
    CrossrefPubMedGoogle Scholar
  • 4 Kodama H, Yamakado K, Takaki H, Suzawa N, Yamada T, Takeda K. Impact of 18F-FDG-PET/CT on treatment strategy in colorectal cancer lung metastasis before lung radiofrequency ablation. Nucl Med Commun 2013; 34 (7) 689-693
    CrossrefPubMedGoogle Scholar
  • 5 Deandreis D, Leboulleux S, Dromain C , et al. Role of FDG PET/CT and chest CT in the follow-up of lung lesions treated with radiofrequency ablation. Radiology 2011; 258 (1) 270-276
    CrossrefPubMedGoogle Scholar
  • 6 Harada S, Sato S, Suzuki E , et al. The usefulness of pre-radiofrequency ablation SUV(max) in 18F-FDG PET/CT to predict the risk of a local recurrence of malignant lung tumors after lung radiofrequency ablation. Acta Med Okayama 2011; 65 (6) 395-402
    PubMedGoogle Scholar
  • 7 Singnurkar A, Solomon SB, Gönen M, Larson SM, Schöder H. 18F-FDG PET/CT for the prediction and detection of local recurrence after radiofrequency ablation of malignant lung lesions. J Nucl Med 2010; 51 (12) 1833-1840
    CrossrefPubMedGoogle Scholar
  • 8 Yu HC, Cheng JS, Lai KH , et al. Factors for early tumor recurrence of single small hepatocellular carcinoma after percutaneous radiofrequency ablation therapy. World J Gastroenterol 2005; 11 (10) 1439-1444
    CrossrefPubMedGoogle Scholar
  • 9 Kinkel K, Lu Y, Both M, Warren RS, Thoeni RF. Detection of hepatic metastases from cancers of the gastrointestinal tract by using noninvasive imaging methods (US, CT, MR imaging, PET): a meta-analysis. Radiology 2002; 224 (3) 748-756
    CrossrefPubMedGoogle Scholar
  • 10 Israel O, Kuten A. Early detection of cancer recurrence: 18F-FDG PET/CT can make a difference in diagnosis and patient care. J Nucl Med 2007; 48 (Suppl. 01) 28S-35S
    PubMedGoogle Scholar
  • 11 Tatli S, Gerbaudo VH, Feeley CM, Shyn PB, Tuncali K, Silverman SG. PET/CT-guided percutaneous biopsy of abdominal masses: initial experience. J Vasc Interv Radiol 2011; 22 (4) 507-514
    CrossrefPubMedGoogle Scholar
  • 12 Prior JO, Kosinski M, Delaloye AB, Denys A. Initial report of PET/CT-guided radiofrequency ablation of liver metastases. J Vasc Interv Radiol 2007; 18 (6) 801-803
    CrossrefPubMedGoogle Scholar
  • 13 Lei P, Dandekar O, Widlus D, Shekhar R. Incorporation of preprocedural PET into CT-guided radiofrequency ablation of hepatic metastases: a nonrigid image registration validation study. J Digit Imaging 2010; 23 (6) 780-792
    CrossrefPubMedGoogle Scholar
  • 14 Giesel FL, Mehndiratta A, Locklin J , et al. Image fusion using CT, MRI and PET for treatment planning, navigation and follow up in percutaneous RFA. Exp Oncol 2009; 31 (2) 106-114
    PubMedGoogle Scholar
  • 15 Sainani NI, Shyn PB, Tatli S, Morrison PR, Tuncali K, Silverman SG. PET/CT-guided radiofrequency and cryoablation: is tumor fluorine-18 fluorodeoxyglucose activity dissipated by thermal ablation?. J Vasc Interv Radiol 2011; 22 (3) 354-360
    CrossrefPubMedGoogle Scholar
  • 16 Schoellnast H, Larson SM, Nehmeh SA, Carrasquillo JA, Thornton RH, Solomon SB. Radiofrequency ablation of non-small-cell carcinoma of the lung under real-time FDG PET CT guidance. Cardiovasc Intervent Radiol 2011; 34 (Suppl. 02) S182-S185
    CrossrefPubMedGoogle Scholar
  • 17 Kuehl H, Stattaus J, Hertel S , et al. Mid-term outcome of positron emission tomography/computed tomography-assisted radiofrequency ablation in primary and secondary liver tumours—a single-centre experience. Clin Oncol (R Coll Radiol) 2008; 20 (3) 234-240
    CrossrefPubMedGoogle Scholar
  • 18 Liu ZY, Chang ZH, Lu ZM, Guo QY. Early PET/CT after radiofrequency ablation in colorectal cancer liver metastases: is it useful?. Chin Med J (Engl) 2010; 123 (13) 1690-1694
    PubMedGoogle Scholar
  • 19 Vogt FM, Antoch G, Veit P , et al. Morphologic and functional changes in nontumorous liver tissue after radiofrequency ablation in an in vivo model: comparison of 18F-FDG PET/CT, MRI, ultrasound, and CT. J Nucl Med 2007; 48 (11) 1836-1844
    CrossrefPubMedGoogle Scholar
  • 20 Purandare NC, Rangarajan V, Shah SA , et al. Therapeutic response to radiofrequency ablation of neoplastic lesions: FDG PET/CT findings. Radiographics 2011; 31 (1) 201-213
    CrossrefPubMedGoogle Scholar
  • 21 Wang XY, Chen D, Zhang XS, Chen ZF, Hu AB. Value of1 F-FDG-PET/CT in the detection of recurrent hepatocellular carcinoma after hepatectomy or radiofrequency ablation: a comparative study with contrast-enhanced ultrasound. J Dig Dis 2013; 14 (8) 433-438
    CrossrefPubMedGoogle Scholar
  • 22 Chen W, Zhuang H, Cheng G, Torigian DA, Alavi A. Comparison of FDG-PET, MRI and CT for post radiofrequency ablation evaluation of hepatic tumors. Ann Nucl Med 2013; 27 (1) 58-64
    CrossrefPubMedGoogle Scholar
  • 23 Nielsen K, van Tilborg AA, Scheffer HJ , et al. PET-CT after radiofrequency ablation of colorectal liver metastases: suggestions for timing and image interpretation. Eur J Radiol 2013; 82 (12) 2169-2175
    CrossrefPubMedGoogle Scholar
  • 24 Hyder O, Dodson RM, Mayo SC , et al. Post-treatment surveillance of patients with colorectal cancer with surgically treated liver metastases. Surgery 2013; 154 (2) 256-265
    CrossrefPubMedGoogle Scholar
  • 25 Ambrogi MC, Lucchi M, Dini P , et al. Percutaneous radiofrequency ablation of lung tumours: results in the mid-term. Eur J Cardiothorac Surg 2006; 30 (1) 177-183
    CrossrefPubMedGoogle Scholar
  • 26 Sharma A, Lanuti M, He W, Palmer EL, Shepard JA, Digumarthy SR. Increase in fluorodeoxyglucose positron emission tomography activity following complete radiofrequency ablation of lung tumors. J Comput Assist Tomogr 2013; 37 (1) 9-14
    CrossrefPubMedGoogle Scholar
  • 27 Pou Ucha JL, Nogueiras Alonso JM, Alvarez Paez AM , et al. Diagnostic yield of baseline and follow-up PET/CT studies in ablative therapy for non-small cell lung cancer. Rev Esp Med Nucl Imagen Mol 2012; 31 (6) 301-307
    PubMedGoogle Scholar
  • 28 Yoo DC, Dupuy DE, Hillman SL , et al. Radiofrequency ablation of medically inoperable stage IA non-small cell lung cancer: are early posttreatment PET findings predictive of treatment outcome?. AJR Am J Roentgenol 2011; 197 (2) 334-340
    CrossrefPubMedGoogle Scholar
  • 29 Suzawa N, Yamakado K, Takao M, Taguchi O, Yamada T, Takeda K. Detection of local tumor progression by (18)F-FDG PET/CT following lung radiofrequency ablation: PET versus CT. Clin Nucl Med 2013; 38 (4) e166-e170
    CrossrefPubMedGoogle Scholar
  • 30 Akeboshi M, Yamakado K, Nakatsuka A , et al. Percutaneous radiofrequency ablation of lung neoplasms: initial therapeutic response. J Vasc Interv Radiol 2004; 15 (5) 463-470
    CrossrefPubMedGoogle Scholar
  • 31 Ryan ER, Sofocleous CT, Schöder H , et al. Split-dose technique for FDG PET/CT-guided percutaneous ablation: a method to facilitate lesion targeting and to provide immediate assessment of treatment effectiveness. Radiology 2013; 268 (1) 288-295
    CrossrefPubMedGoogle Scholar
  • 32 Bao A, Goins B, Dodd III GD , et al. Real-time iterative monitoring of radiofrequency ablation tumor therapy with 15O-water PET imaging. J Nucl Med 2008; 49 (10) 1723-1729
    CrossrefPubMedGoogle Scholar
  • 33 Venkatesan AM, Kadoury S, Abi-Jaoudeh N , et al. Real-time FDG PET guidance during biopsies and radiofrequency ablation using multimodality fusion with electromagnetic navigation. Radiology 2011; 260 (3) 848-856
    CrossrefPubMedGoogle Scholar
  • 34 Wood BJ, Locklin JK, Viswanathan A , et al. Technologies for guidance of radiofrequency ablation in the multimodality interventional suite of the future. J Vasc Interv Radiol 2007; 18 (1 Pt 1) 9-24
    CrossrefPubMedGoogle Scholar
  • 35 Pichler BJ, Kolb A, Nägele T, Schlemmer HP. PET/MRI: paving the way for the next generation of clinical multimodality imaging applications. J Nucl Med 2010; 51 (3) 333-336
    CrossrefPubMedGoogle Scholar